Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 4, 2011, Pages 659-667

  Kim, Beom Kyung ^a   Park, Jun Yong ^a   Choi, Hye Jin ^a   Kim, Do Young ^a   Ahn, Sang Hoon ^a   Kim, Ja Kyung ^a   Lee, Do Youn ^a   Lee, Kwang Hoon ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Cisplatin; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Prognosis

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE METASTASIS; CANCER CONTROL; CANCER RADIOTHERAPY; CATHETER INFECTION; CATHETER OCCLUSION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TOXICITY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 79954450480     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0917-5     Document Type: Article

References (31)

1. E Ando M Tanaka F Yamashita, et al. 2002 Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases Cancer 95 588 595 12209752 10.1002/cncr.10694 (Pubitemid 34810185)
2. L Bedenne C Milan A Pariente, et al. 2005 Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma J Clin Oncol 23 4338 4346 15994145 10.1200/JCO.2005.05.470 (Pubitemid 46207007)
3. J Bruix A Burroughs JM Llovet 2003 Hepatocellular carcinoma Lancet 362 1907 1917 14667750 10.1016/S0140-6736(03)14964-1 (Pubitemid 37518510)
4. SL Chan FK Mo PJ Johnson, et al. 2009 New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 446 452 19064965 10.1200/JCO.2008.18.8151 1:CAS:528:DC%2BD1MXitF2gtr0%3D
5. AL Cheng YK Kang Z Chen, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25 34 19095497 10.1016/S1470-2045(08)70285-7 1:CAS:528:DC%2BD1cXhsFChtbnM
6. E Frei G Steele S Come, et al. 1978 A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil Cancer Res 38 3784 3792 151583
7. A Ganeshan S Upponi LQ Hon, et al. 2008 Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology Ann Oncol 19 847 851 18029972 10.1093/annonc/mdm528 1:STN:280:DC%2BD1c3nvV2rtg%3D%3D (Pubitemid 351627299)
8. SG Gwyther MC Christian AT van Oosterom, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205
9. KH Han JY Park 2008 Chemotherapy for advanced hepatocellular carcinoma J Gastroenterol Hepatol 23 682 684 18410601 10.1111/j.1440-1746.2008.05444.x 1:CAS:528:DC%2BD1cXmsFehtrc%3D (Pubitemid 351519441)
10. M Ikeda T Okusaka H Ueno, et al. 2007 Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis Oncology 72 188 193 18097170 10.1159/000112805 1:CAS:528:DC%2BD1cXptlKksg%3D%3D (Pubitemid 351161608)
11. T Ishikawa M Imai H Kamimura, et al. 2007 Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study World J Gastroenterol 13 5465 5470 17907289 1:CAS:528:DC%2BD2sXhtlSqu7vP (Pubitemid 47610990)
12. T Itamoto H Nakahara H Tashiro, et al. 2002 Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein J Surg Oncol 80 143 148 12115797 10.1002/jso.10116 1:CAS:528:DC%2BD38XlvFKktrY%3D (Pubitemid 34747619)
13. PG Johnston F Geoffrey J Drake, et al. 1996 The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line Eur J Cancer 32A 2148 2154 9014759 10.1016/S0959-8049(96)00266-3 1:CAS:528: DyaK2sXpt1Wmtw%3D%3D (Pubitemid 26419467)
14. K Kobayashi A Tsuji S Morita, et al. 2006 A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma BMC Cancer 6 121 16677397 10.1186/1471-2407-6-121 (Pubitemid 43970749)
15. M Kurihara T Shirasaka M Matsukawa, et al. 1999 Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves Clin Cancer Res 5 2620 2628 10499641 (Pubitemid 29437350)
16. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
17. T Nakano S Ohmori M Deguchi, et al. 2003 Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma Anticancer Res 23 1719 1722 12820447 (Pubitemid 36750837)
18. JW Park 2004 Practice guideline for diagnosis and treatment of hepatocellular carcinoma Korean J Hepatol 10 88 98 15218342
19. JY Park SH Ahn YJ Yoon, et al. 2007 Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma Cancer 110 129 137 17508408 10.1002/cncr.22759 (Pubitemid 46986425)
20. Pisani P, Ferlay J, Bray F et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
21. KR Reddy L Rudolph JA Marrero, et al. 2008 Diagnosis and treatment of hepatocellular carcinoma Gastroenterology 134 1752 1763 18471552 10.1053/j.gastro.2008.02.047 (Pubitemid 351615415)
22. A Riaz RK Ryu LM Kulik, et al. 2009 Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival J Clin Oncol 27 5734 5742 19805671 10.1200/JCO.2009.23.1282 1:CAS:528:DC%2BC3cXhtVWisbs%3D
23. S Saji Y Sugiyama A Matsuo, et al. 2004 Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel Int J Oncol 24 807 813 15010816
24. M Sherman J Bruix 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 16250051 10.1002/hep.20790 (Pubitemid 40911304)
25. AN Tse N Wu D Patel, et al. 2009 A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies Cancer Chemother Pharmacol 64 935 944 19221752 10.1007/s00280-009-0945-5 1:CAS:528:DC%2BD1MXhtVSitLzJ
26. SR Vora H Zheng ZK Stadler, et al. 2009 Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma Oncologist 14 717 725 19581525 10.1634/theoncologist.2009-0038 1:CAS:528:DC%2BD1MXhtVOmtrnL
27. HY Woo SH Bae JY Park, et al. 2010 A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma Cancer Chemother Pharmacol 65 373 382 19763572 10.1007/s00280-009-1126-2 1:CAS:528:DC%2BD1MXhsVKnsL%2FP
28. T Yamasaki T Kimura F Kurokawa, et al. 2005 Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy J Gastroenterol 40 70 78 15692792 10.1007/s00535-004-1494- 7 1:CAS:528:DC%2BD2MXhtVamsbo%3D (Pubitemid 40796335)
29. M Yoshikawa N Ono H Yodono, et al. 2008 Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma Hepatol Res 38 474 483 18430093 10.1111/j.1872-034X. 2008.00338.x 1:CAS:528:DC%2BD1cXptlajsLw%3D (Pubitemid 351593948)
30. AX Zhu JW Clark 2009 Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy Oncologist 14 67 69 19147690 10.1634/theoncologist.2008-0281
31. AX Zhu Y Yen LW Goff, et al. 2009 NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 350 391 19406039